Evidence map›Paper›PMID 26414379›Full record

ArticlePloS one2015

Ex-Ante Economic Impact Assessment of Genetically Modified Banana Resistant to Xanthomonas Wilt in the Great Lakes Region of Africa.

John Herbert Ainembabazi, Leena Tripathi, Joseph Rusike, Tahirou Abdoulaye, Victor Manyong

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Application of CRISPR/Cas-based gene-editing for developing better banana.Frontiers in bioengineering and biotechnology · 2024
    Review
  5. Review
  6. Advances in Somatic Embryogenesis of Banana.International journal of molecular sciences · 2023
    Review
  7. Article
  8. Control of Bacterial Diseases of Banana Using CRISPR/Cas-Based Gene Editing.International journal of molecular sciences · 2022
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

John Herbert AinembabaziInternational Institute of Tropical Agriculture (IITA), Kampala, Uganda.
Leena TripathiInternational Institute of Tropical Agriculture (IITA), Nairobi, Kenya.
Joseph RusikeInternational Institute of Tropical Agriculture (IITA), Dar es Salaam, Tanzania; Alliance for a Green Revolution in Africa (AGRA), Nairobi, Kenya.
Tahirou AbdoulayeInternational Institute of Tropical Agriculture (IITA), Ibadan, Nigeria.
Victor ManyongInternational Institute of Tropical Agriculture (IITA), Dar es Salaam, Tanzania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCredible empirical evidence is scanty on the social implications of genetically modified (GM) crops in Africa, especially on vegetatively propagated crops. Little is known about the future success of introducing GM technologies into staple crops such as bananas, which are widely produced and consumed in the Great Lakes Region of Africa (GLA). GM banana has a potential to control the destructive banana Xanthomonas wilt disease.

objectiveTo gain a better understanding of future adoption and consumption of GM banana in the GLA countries which are yet to permit the production of GM crops; specifically, to evaluate the potential economic impacts of GM cultivars resistant to banana Xanthomonas wilt disease. DATA SOURCES: The paper uses data collected from farmers, traders, agricultural extension agents and key informants in the GLA. ANALYSIS: We analyze the perceptions of the respondents about the adoption and consumption of GM crop. Economic surplus model is used to determine future economic benefits and costs of producing GM banana.

resultsOn the release of GM banana for commercialization, the expected initial adoption rate ranges from 21 to 70%, while the ceiling adoption rate is up to 100%. Investment in the development of GM banana is economically viable. However, aggregate benefits vary substantially across the target countries ranging from US$ 20 million to 953 million, highest in countries where disease incidence and production losses are high, ranging from 51 to 83% of production.

conclusionThe findings support investment in the development of GM banana resistant to Xanthomonas wilt disease. The main beneficiaries of this technology development are farmers and consumers, although the latter benefit more than the former from reduced prices. Designing a participatory breeding program involving farmers and consumers signifies the successful adoption and consumption of GM banana in the target countries.

Indexed as

AfricaAgricultureDisease ResistanceLakesMusaPlant DiseasesPlants, Genetically ModifiedXanthomonas

Identifiers

PMID26414379
PMCPMC4587572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.